TL;DR
This study investigated the cardiac safety of azithromycin (AZM) and hydroxychloroquine (HCQ), alone and in combination, in guinea pigs. The findings indicate that AZM significantly prolongs the QT interval and impairs cardiac function, while the HCQ+AZM combination exacerbates cardiac dysfunction compared to HCQ alone.
What Problem Does This Paper Address?
During the early stages of the COVID-19 pandemic, hydroxychloroquine (HCQ) and azithromycin (AZM) were widely explored as potential treatments. However, concerns arose regarding their cardiotoxicity, with conflicting results from clinical trials and observational studies. To address this uncertainty and re-evaluate the safety profiles of these drugs, especially for non-COVID-19 applications, this research aimed to assess the impact of short-term AZM or HCQ + AZM treatment on cardiac conduction and function in a preclinical animal model. This is crucial for understanding potential risks and informing safe drug usage.
Methods
The study utilized a preclinical animal model, employing 32 male guinea pigs randomly assigned to four groups: control (CON), azithromycin (AZM) alone, hydroxychloroquine (HCQ) alone, and a combination of HCQ + AZM. Over a 9-day period, the animals received daily drug administrations.
Key techniques included:
- Electrocardiography (ECG): Used to monitor cardiac electrical activity. Specifically, the study focused on parameters like the QT interval (reflecting ventricular repolarization), RR interval (heart rate), PR interval (atrial-ventricular conduction), and QRS duration (ventricular depolarization). A critical aspect was the evaluation and selection of the most appropriate QT interval correction formula (Van de Water's method was chosen for its superior correlation) to account for heart rate variations.
- Transthoracic Echocardiography: Employed to assess cardiac morphology and function. This involved measuring left ventricular dimensions (diastolic and systolic), posterior wall thickness, end-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (LVEF), and fractional shortening (LVFS).
These methods allowed for a comprehensive evaluation of both the electrical and mechanical aspects of cardiac health.
Datasets
Not discussed in the paper. The study utilized data collected from the experimental guinea pig model.
Key Insights and Ideas
- AZM's Independent Cardiac Risk: The study strongly suggests that azithromycin, even when used alone, poses a significant risk to cardiac health by prolonging the QT interval and reducing left ventricular ejection fraction and fractional shortening. This highlights that AZM's cardiotoxicity is not solely dependent on its combination with HCQ.
- Synergistic Cardiotoxicity of HCQ + AZM: The combination therapy of HCQ and AZM demonstrated a more pronounced negative impact on cardiac function than HCQ alone. This suggests a potential synergistic or additive cardiotoxic effect when these drugs are administered together, increasing the risk of cardiac dysfunction.
- HCQ's Limited Acute Cardiotoxicity in Healthy Animals: In healthy guinea pigs, short-term HCQ monotherapy did not significantly alter QT interval or cardiac function parameters. This finding aligns with some previous studies but contrasts with observations in COVID-19 patients, hinting that underlying disease conditions might exacerbate HCQ's cardiac risks.
- Importance of Preclinical Models for Drug Safety: The study underscores the value of preclinical animal models in identifying potential cardiotoxic effects of drugs before they are widely used in humans, especially when clinical data is conflicting or limited.
Key Results
- QT Interval Prolongation: Both AZM and HCQ + AZM treatments significantly increased the corrected QT (QTc) interval on days 3, 6, and 9 compared to the control group. HCQ alone did not significantly affect the QTc interval.
- Cardiac Function Impairment:
- AZM treatment significantly decreased LVEF and LVFS on days 3, 6, and 9.
- HCQ + AZM treatment significantly decreased LVEF and LVFS only on day 9.
- Compared to CON, AZM and HCQ alone decreased EDV.
- Compared to HCQ alone, HCQ + AZM treatment increased ESV on day 9.
- Heart Rate: AZM decreased heart rates on day 9, while HCQ + AZM decreased heart rates on days 3, 6, and 9.
- Conduction: AZM prolonged the PR interval. The HCQ + AZM treatment also affected PR interval on day 6. QRS complex durations remained largely unaffected across groups.
Limitations and Future Work
The authors acknowledge the following limitations:
- Single Dose Study: The study explored the effects of AZM and HCQ + AZM at a single dose. Future research should investigate a range of doses (higher and lower) to fully understand the dose-dependent cardiotoxicity.
- Healthy Animal Model: The study used healthy guinea pigs. To better mimic the conditions in COVID-19 patients, future studies could explore models that resemble SARS-CoV-2 induced cardiac damage, as disease-related cardiac injury might influence drug cardiotoxicity.
Promising future directions suggested include:
- Molecular Mechanisms: Investigating protein expression alterations in cellular membrane receptors and their downstream signals to elucidate the underlying molecular mechanisms of cardiotoxicity.
- Long-term Effects: Assessing the long-term cardiac effects of these drugs and their withdrawal.
Summary updated